SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. The company designs, develops, and manufactures genetic analysis technologies. It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing. The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc. It serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations. The company was founded in 2013 and is based in Billerica, Massachusetts.
P/E ratio for SeqLL Inc. (SQL)
P/E ratio as of 2023: 0.00
According to SeqLL Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.00. At the end of 2022 the company had a P/E ratio of -0.83.
P/E ratio history for SeqLL Inc. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | -0.83 |
| 2021 | -3.45 |
| 2020 | -14.49 |
| 2019 | -8.32 |
| 2018 | -7.65 |
| 2017 | -31.11 |